scholarly journals IMMUNOGRAPH-BASED ANALYSIS OF THE INFLUENZA A (H1N1)PDM09 VACCINE STRAIN IMMUNOGENICITY IN THE PANDEMIC AND POST-PANDEMIC PERIOD (2009-2014)

2021 ◽  
Author(s):  
V. S. Vakin ◽  
I. V. Amosova ◽  
E. M. Vojcekhovskaya ◽  
T. A. Timoshicheva ◽  
A. A. Vasileva ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Level ◽  
Influenza A ◽  
Influenza Viruses ◽  
Influenza Vaccines ◽  
High Antibody ◽  
Serum Antibodies ◽  
Influenza A H1n1 ◽  
Antibody Titers ◽  
Immunogenic Properties

Currently, the assessment of the immunogenic properties of influenza viruses as a part of influenza vaccines, is carried out by using seroprotection, seroconversion as well as the rate of increases in post-vaccination antibodies. At the same time, significant differences in the immunogenicity of vaccines related to dynamic formation of high antibody titers responsible for long-term protection of the vaccinated, are neglected.Influenza viruses such as A (H1N1) pdm09 that caused 2009-2010 pandemic continue to circulate in the population, therefore, the assessment of the immunogenic activity of vaccine viruses prepared during the pandemic period is interesting in for the methodology to prepare pandemic vaccines to be used in various groups (adults, children, elderly people).Analyzing immunogenicity of influenza vaccines used during the 2009-10 swine influenza pandemic and the post-pandemic period up to the year 2014 was carried out by applying the graphical method for assessing immunogenicity (immunographs) measured as follows: for each group of vaccinated subjects (depending on the vaccine used), an increased rate in antibody level was calculated and the graphs of immunogenicity were plotted. An increased rate of serum antibodies magnitude from vaccinated subjects and the number of sera (in%) with a given fold increase rate in antibody level from 1 to the maximum magnitude were plotted on the x- and y-axis, respectively. The proposed method for assessing immunogenicity allows to plot immunogenicity graphs regardless of the serum antibodies level found in volunteers. The assessment described above revealed a several features for developing immune response to the pandemic virus A (H1N1)pdm09 such as the lack of immune response in a substantial number of adult volunteers (25-27%%) and young children (60-70%%) after monovaccine administration. The reason for such immune response can be both an insufficient dose of vaccine-containing viral antigen and suppressed immune response caused by the influenza A(H1N1)pdm09.A study on the immunogenic properties for seasonal influenza vaccines containing the influenza A (H1N1) pdm09 virus antigen in the years 2010 - 2014 revealed a variety in emerging humoral immunity ranging from a short-term, low-frequency increase in antibodies from vaccinated children to the formation of high antibody titers in elderly.Practically, immunographic analysis of influenza vaccines particularly those derived from the influenza A (H1N1)pdm09 virus, may result in proposing recommendations to increase an antigenic load at the beginning of a pandemic cycle and/or block the suppressive properties of vaccine-contained viruses in pediatric vaccines, because escalating virus dose in the vaccine may not always be achievable in this case.

scholarly journals Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 434 ◽  
Author(s):  
Christopher E. Lopez ◽  
Kevin L. Legge
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Virus Infection ◽  
Influenza A ◽  
Influenza Virus Infection ◽  
Influenza Viruses ◽  
Antigenic Drift ◽  
Influenza Vaccines ◽  
Virus Infections ◽  
Universal Vaccine

Influenza virus infections represent a serious public health threat and account for significant morbidity and mortality worldwide due to seasonal epidemics and periodic pandemics. Despite being an important countermeasure to combat influenza virus and being highly efficacious when matched to circulating influenza viruses, current preventative strategies of vaccination against influenza virus often provide incomplete protection due the continuous antigenic drift/shift of circulating strains of influenza virus. Prevention and control of influenza virus infection with vaccines is dependent on the host immune response induced by vaccination and the various vaccine platforms induce different components of the local and systemic immune response. This review focuses on the immune basis of current (inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV)) as well as novel vaccine platforms against influenza virus. Particular emphasis will be placed on how each platform induces cross-protection against heterologous influenza viruses, as well as how this immunity compares to and contrasts from the “gold standard” of immunity generated by natural influenza virus infection.

scholarly journals Immunogenicity of Modern Vaccine Viruses of Influenza A (H1N1)pdm09 According to Graphical Analysis

2017 ◽  
Vol 16 (5) ◽  
pp. 28-32
Author(s):  
V. S. Vakin ◽  
O. S. Konshina ◽  
E. M. Wojciechowska ◽  
E. V. Kuznetsova ◽  
V. G. Mayorova ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Influenza A ◽  
Graphical Analysis ◽  
Graphical Form ◽  
Influenza Virus A ◽  
Methods Of Evaluation ◽  
Limited Effectiveness ◽  
Influenza A H1n1 ◽  
Antibody Titers

Antiepidemic measures were limited effectiveness for several years Objectives of this research were formulated as an assessment of the immunogenicity activity of the influenza virus A(H1N1)pdm09 in the composition of modern trivaccines Immunogenicity of the influenza virus A(H1N1)pdm09 in the vaccinated by vaccine was assessed by graphing, reflecting the dynamics of the multiplicity growth of antibodies (MG) and medium ratio of antibodies increasing (MR) in sera for several groups vaccinated. For comparison of vaccinated immunity was determined by traditional methods of evaluation of the immune response. As a result of the research, differences in the immunogenicity activity of the virus were revealed, which are reflected in antibody titers and the multiplicities of their growth from 2 to 4 - 8 times with the applying of similar quality vaccines. These changes couldn’t be observed with accounting study of the immune response. When immunized with a vaccine with an antigen dose of 5 mg HA identified a group of«silent» volunteers (8%) who did not respond to promotion with antigen A(H1N1)pdm09. Increasing dose of the influenza virus A(H1N1)pdm09 to 15 mg/dose in the split vaccine were result of the elimination of the group of«silent» volunteers. Simultaneously was observed a significant increase in the immune response in serum titers (up to 32-fold) and antibody growth rates Accordingly, using of the graphical form of accounting made it possible to better assess the details of the formation of collective immunity to the virus A(H1N1)pdm09 and the nature of its deviations in a number of cases.

scholarly journals Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines

mBio ◽  
2019 ◽  
Vol 10 (5) ◽  
Author(s):  
Pui Wang ◽  
Min Zheng ◽  
Siu-Ying Lau ◽  
Pin Chen ◽  
Bobo Wing-Yee Mok ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
T Cell ◽  
Protective Immunity ◽  
Influenza A ◽  
Influenza Viruses ◽  
Cross Protection ◽  
Influenza Vaccines ◽  
Influenza B ◽  
Ns1 Protein

ABSTRACT Nonstructural protein 1 (NS1) of influenza virus is a key virulence element with multifunctional roles in virus replication and a potent antagonist of host immune response. Deletion of NS1 (DelNS1) would create a safer and more extensively immunogenic live attenuated influenza virus (LAIV) vaccine. However, DelNS1 viruses are very difficult to grow in regular vaccine-producing systems, which has hampered the application of DelNS1 LAIV vaccines in humans. We have developed two master backbones of deleted-NS1 (DelNS1) viral genomes from influenza A or B viruses which contain novel adaptive mutations to support DelNS1-LAIV replication. These DelNS1-LAIVs are highly attenuated in human cells in vitro and nonpathogenic in mice but replicate well in vaccine-producing cells. Both influenza A and influenza B DelNS1 LAIVs grow better at 33°C than at 37 to 39°C. Vaccination with DelNS1 LAIV performed once is enough to provide potent protection against lethal challenge with homologous virus and strong long-lasting cross protection against heterosubtypic or antigenically distantly related influenza viruses in mice. Mechanistic investigations revealed that DelNS1-LAIVs induce cross protective neutralizing antibody and CD8+ and CD4+ T cell immunities. Importantly, it has been shown that DelNS1-LAIV can be used to enhance specific anti-influenza immunity through expression of additional antigens from the deleted-NS1 site. Generation of DelNS1 viruses which are nonpathogenic and able to grow in vaccine-producing systems is an important strategy for making highly immunogenic LAIV vaccines that induce broad cross protective immunity against seasonal and emerging influenza. IMPORTANCE Current seasonal influenza vaccines are suboptimal and low in immunogenicity and do not provide long-lasting immunity and cross protection against influenza virus strains that have antigenically drifted. More-effective influenza vaccines which can induce both humoral immunity and T cell immunity are needed. The NS1 protein of influenza virus is a virulence element and the critical factor for regulation of the host immune response during virus infection. Deletion of the NS1 protein is a strategy to make an optimal LAIV vaccine. However, DelNS1 viruses are very difficult to grow in regular vaccine-producing systems, hampering the application of DelNS1 LAIV vaccines in humans. We have generated a panel of both influenza A and influenza B DelNS1 LAIVs which are able to grow in regular vaccine-producing cells. These DelNS1 LAIV vaccines are completely nonpathogenic, exhibit potent and long-lasting immunity, and can be used to express extra viral antigen to induce cross protective immunity against seasonal and emerging influenza.

scholarly journals Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age‐Dependent Manner

2010 ◽  
Vol 202 (11) ◽  
pp. 1634-1638 ◽  
Author(s):  
Glendie Marcelin ◽  
Hilliary M. Bland ◽  
Nicholas J. Negovetich ◽  
Matthew R. Sandbulte ◽  
Ali H. Ellebedy ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Influenza Vaccines ◽  
Dependent Manner ◽  
Serum Antibodies ◽  
Influenza A H1n1 ◽  
Age Dependent

scholarly journals PRESENCE OF RESPIRATORY VIRUSES IN EQUINES IN BRAZIL

2014 ◽  
Vol 56 (3) ◽  
pp. 191-195
Author(s):  
Dalva Assunção Portari Mancini ◽  
Aparecida Santo Pietro Pereira ◽  
Rita Maria Zucatelli Mendonça ◽  
Adelia Hiroko Nagamori Kawamoto ◽  
Rosely Cabette Barbosa Alves ◽  
...  
Keyword(s):  
Influenza A ◽  
Respiratory Viruses ◽  
Influenza Viruses ◽  
Influenza A Viruses ◽  
Equine Influenza ◽  
Hemagglutination Inhibition Test ◽  
Parainfluenza Viruses ◽  
Significant Difference ◽  
Antibody Titers ◽  
The Difference

Equines are susceptible to respiratory viruses such as influenza and parainfluenza. Respiratory diseases have adversely impacted economies all over the world. This study was intended to determine the presence of influenza and parainfluenza viruses in unvaccinated horses from some regions of the state of São Paulo, Brazil. Blood serum collected from 72 equines of different towns in this state was tested by hemagglutination inhibition test to detect antibodies for both viruses using the corresponding antigens. About 98.6% (71) and 97.2% (70) of the equines responded with antibody protective titers (≥ 80 HIU/25µL) H7N7 and H3N8 subtypes of influenza A viruses, respectively. All horses (72) also responded with protective titers (≥ 80) HIU/25µL against the parainfluenza virus. The difference between mean antibody titers to H7N7 and H3N8 subtypes of influenza A viruses was not statistically significant (p > 0.05). The mean titers for influenza and parainfluenza viruses, on the other hand, showed a statistically significant difference (p < 0.001). These results indicate a better antibody response from equines to parainfluenza 3 virus than to the equine influenza viruses. No statistically significant differences in the responses against H7N7 and H3N8 subtypes of influenza A and parainfluenza 3 viruses were observed according to the gender (female, male) or the age (≤ 2 to 20 years-old) groups. This study provides evidence of the concomitant presence of two subtypes of the equine influenza A (H7N7 and H3N8) viruses and the parainfluenza 3 virus in equines in Brazil. Thus, it is advisable to vaccinate equines against these respiratory viruses.

scholarly journals Influenza: An Emerging and Re-emerging Public Health Threat in Nepal

2018 ◽  
Vol 3 (2) ◽  
pp. 1-2
Author(s):  
Bishnu Prasad Upadhyay
Keyword(s):  
Influenza Virus ◽  
Influenza A ◽  
Winter Season ◽  
Emerging Infectious Diseases ◽  
Influenza Viruses ◽  
Influenza B ◽  
Influenza A Viruses ◽  
Influenza A H1n1 ◽  
New Variant ◽  
Seasonal Epidemics

Influenza virus type A and B are responsible for seasonal epidemics as well as pandemics in human. Influenza A viruses are further divided into two major groups namely, low pathogenic seasonal influenza (A/H1N1, A/H1N1 pdm09, A/H3N2) and highly pathogenic influenza virus (H5N1, H5N6, H7N9) on the basis of two surface antigens: hemagglutinin (HA) and neuraminidase (NA). Mutations, including substitutions, deletions, and insertions, are one of the most important mechanisms for producing new variant of influenza viruses. During the last 30 years; more than 50 viral threat has been evolved in South-East Asian countriesof them influenza is one of the major emerging and re-emerging infectious diseases of global concern. Similar to tropical and sub-tropical countries of Southeast Asia; circulation of A/H1N1 pdm09, A/H3N2 and influenza B has been circulating throughout the year with the peak during July-November in Nepal. However; the rate of infection transmission reach peak during the post-rain and winter season of Nepal.

Modeling and simulation of the spread of H1N1 flu with periodic vaccination

2015 ◽  
Vol 09 (01) ◽  
pp. 1650003 ◽  
Author(s):  
Islam A. Moneim
Keyword(s):  
Influenza A ◽  
Vaccination Strategy ◽  
Vaccination Rate ◽  
Influenza Viruses ◽  
Sirs Epidemic Model ◽  
Sirs Model ◽  
Influenza A H1n1 ◽  
Large Populations ◽  
Stability Results ◽  
Influenza H1n1

Influenza H1N1 has been found to exhibit oscillatory levels of incidence in large populations. Clear peaks for influenza H1N1 are observed in several countries including Vietnam each year [M. F. Boni, B. H. Manh, P. Q. Thai, J. Farrar, T. Hien, N. T. Hien, N. Van Kinh and P. Horby, Modelling the progression of pandemic influenza A (H1N1) in Vietnam and the opportunities for reassortment with other influenza viruses, BMC Med. 7 (2009) 43, Doi: 10.1186/1741-7015-7-43]. So it is important to study seasonal forces and factors which can affect the transmission of this disease. This paper studies an SIRS epidemic model with seasonal vaccination rate. This SIRS model has a unique disease-free solution (DFS). The value R0, the basic reproduction number is obtained when the vaccination is a periodic function. Stability results for the DFS are obtained when R0 < 1. The disease persists in the population and remains endemic if R0 > 1. Also when R0 > 1 existence of a nonzero periodic solution is proved. These results obtained for our model when the vaccination strategy is a non-constant time-dependent function.

scholarly journals Postnatal decline of maternally acquired viral antibodies of different specificities

1971 ◽  
Vol 69 (3) ◽  
pp. 435-444 ◽  
Author(s):  
M. J. Cloonan ◽  
R. A. Hawkes ◽  
L. H. Stevens
Keyword(s):  
Antibody Titre ◽  
Half Life ◽  
Influenza A ◽  
High Antibody ◽  
Serum Antibodies ◽  
Rectangular Hyperbola ◽  
Viral Antibodies ◽  
Antibody Titres ◽  
Type 3 ◽  
Rubella Antibody

SUMMARYThe rates of decline (half-lives) of maternally acquired antibodies of two different specificities in a group of infants were found to be highly variable, ranging from 18 to 192 days for parainfluenza type 3 antibody (54 infants) and from 15 to 251 days for influenza A2 antibody (nine infants). For antibodies of both specificities approximately 75% of the half-lives were between 15 and 60 days. With parainfluenza type 3 antibody, and possibly with influenza A 2 antibody, the half-lives were inversely proportional to the initial antibody titre of the babies' sera. This relationship could be described by a rectangular hyperbola. Babies with high antibody titres at birth lost this antibody rapidly whereas in babies with low initial titres antibody declined over a longer period.The half-lives of parainfluenza type 3 antibody and influenza A 2 antibody were compared with that of rubella antibody in the same group of infants (previously published). Maternally acquired viral antibodies of different specificities did not necessarily decline at similar rates in any given child. In nine infants, maternally acquired antibodies of two different specificities (rubella and parainfluenza type 3) declined at significantly different rates in the same child. It is suggested that although the half-life of antibody of a given specificity is related to its concentration in the serum, it is independent of the level of serum antibodies of other specificities.

Sign in / Sign up

Export Citation Format

Share Document